Ipamorelin side effects: what the literature reports
The cleanest GHRP profile in the literature is not the same as no profile.
TL;DR
- Ipamorelin is among the cleanest GHRPs (in plain English: small molecules that signal the pituitary to release growth hormone).
- The most common reported effects are injection-site reactions, transient flushing, mild headache, and temporary hunger.
- Compounded ipamorelin is not FDA-approved. Side-effect tracking is a physician's job, not a self-managed checklist.
What it is
Ipamorelin is a synthetic GHRP (growth hormone-releasing peptide) developed in the late 1990s. Its appeal in the literature is what it does not do: it triggers a growth hormone pulse without meaningfully raising cortisol or prolactin in healthy-adult dose ranges (Raun et al., Eur J Endocrinol, 1998).
How it works
Picture a doorbell with five buttons. Older GHRPs press the growth hormone button — and accidentally lean on the cortisol and prolactin buttons too. Ipamorelin presses just the one button. That selectivity, demonstrated in animal and early human pharmacology, is the reason it shows up in modern physician protocols (Gobburu et al., Clin Pharmacokinet, 2004).
Who asks about it
People usually ask about side effects after reading marketing copy that calls ipamorelin "side-effect free." It is not. It is cleaner, in the sense that the unwanted bell presses are quieter. That is a real advantage. It is not the same as zero risk.
What the research says
In dose-finding studies in healthy adults, the most common observations were injection-site irritation, transient flushing, lightheadedness during the first hour after injection, and a temporary increase in appetite (consistent with growth hormone secretagogue activity). Headache and mild fatigue have been reported. Cortisol and prolactin elevations seen with GHRP-6 and GHRP-2 are largely absent at studied ipamorelin doses (Raun et al., 1998). Long-term human data is limited.
What to know before considering it
Ipamorelin is not appropriate for people with active cancer, certain pituitary conditions, or untreated retinopathy. Anyone on insulin or diabetes medication should be monitored — growth hormone activity can shift insulin sensitivity. Compounded ipamorelin is not FDA-approved. Side-effect monitoring should happen alongside a licensed physician.
The Halftime POV
A compound being "clean" in the literature is not a green light. It is a starting point. The honest move is to begin low, monitor labs and lived response together, and treat any unusual symptom — even a mild one — as worth a physician conversation.
Related reading:
- Ipamorelin: what this GHRP peptide is
- Ipamorelin research: published evidence reviewed
- CJC-1295 + Ipamorelin: why they are often combined
FAQ
Q: What are the most common ipamorelin side effects? A: Published trials and case reports describe injection-site reactions, mild headache, transient flushing, lightheadedness, and a temporary increase in hunger. Most reactions are short-lived. Effects on cortisol and prolactin in the studied dose ranges are minimal compared with older GHRPs.
Q: Does ipamorelin raise cortisol? A: Compared with earlier GHRPs (GHRP-2 and GHRP-6), ipamorelin shows little to no effect on cortisol or prolactin in healthy-adult dosing studies. This is one reason physicians often select it over those older compounds.
Q: Is ipamorelin FDA-approved? A: No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
- Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin. Clinical Pharmacokinetics, 2004.
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
What are the most common ipamorelin side effects?
Published trials and case reports describe injection-site reactions, mild headache, transient flushing, lightheadedness, and a temporary increase in hunger. Most reactions are short-lived. Effects on cortisol and prolactin in the studied dose ranges are minimal compared with older GHRPs.
Does ipamorelin raise cortisol?
Compared with earlier GHRPs (GHRP-2 and GHRP-6), ipamorelin shows little to no effect on cortisol or prolactin in healthy-adult dosing studies. This is one reason physicians often select it over those older compounds.
Is ipamorelin FDA-approved?
No. Ipamorelin is not FDA-approved as a finished drug product. Compounded ipamorelin is not FDA-approved. As of September 14, 2026, ipamorelin is not in any FDA 503A category and is not on the 503A bulks list. Any use requires a licensed prescriber's evaluation.
Keep reading
A licensed physician reviews your labs and builds your protocol.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.